Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Artios announces first patient dosed in randomized Phase 2 POLKA study evaluating DNA Polθ inhibitor ART6043 in gBRCA-mutated HER2-negative breast cancer.
-
CAMBRIDGE, United Kingdom and NEW YORK, May 12, 2026 – Artios Pharma Limited (“Artios”), a clinical-stage biopharmaceutical company pioneering the development of new classes of DNA Damage Response...
-
Jeremy B. Fitch, MBA, appointed as Chief Business OfficerMichael A. Alrutz, J.D., Ph.D., appointed as General CounselGuy C. Ruble, PharmD, appointed as VP, Regulatory Affairs CAMBRIDGE, United...
-
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with HGSOC
-
Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer
-
Artios appoints Roy Ware (CMTO), Caryn Barnett (VP Clinical Operations) & Pablo Lee (VP Medical Affairs) to strengthen late-stage development capabilities
-
Artios Pharma to present at the 2026 J.P. Morgan Healthcare Conference, highlighting its ATR and Polθ inhibitor programs targeting DDR in cancer.
-
Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib Following encouraging ESMO...
-
Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...
-
CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage...